Valuation : Ocular Therapeutix, Inc.

Market Cap 2.39B 2.06B 1.93B 1.77B 3.3B 226B 3.33B 22.86B 8.9B 116B 8.99B 8.79B 372B P/E 2026 *
-7.31x
P/E 2027 * -7.82x
Enterprise Value 2.02B 1.73B 1.63B 1.49B 2.78B 191B 2.8B 19.25B 7.5B 97.38B 7.57B 7.4B 314B EV / Sales 2026 *
38.1x
EV / Sales 2027 * 22.7x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Ocular Therapeutix, Inc.

1 day-3.12%
1 week-2.30%
Current month+0.77%
1 month+25.85%
3 months+26.60%
6 months-1.76%
Current year-12.92%
1 week 10.13
Extreme 10.13
11.08
1 month 8.36
Extreme 8.355
11.74
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 14/04/2024
Director of Finance/CFO 50 19/01/2026
Chief Tech/Sci/R&D Officer 49 19/05/2024
Director TitleAgeSince
Chairman 57 30/06/2019
Director/Board Member 78 04/11/2012
Director/Board Member 66 19/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Don

Chief Executive Officer

-100,184 0.0473%
24/08/26 Sell

Executive/Senior Manager

-3,035 0.0014%
24/08/26 Sell

Chief Technology Officer

-3,296 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-2.98%-2.30%-18.31%+169.67% 2.39B
+0.22%-1.30%+57.33%+107.97% 1,034B
+1.18%+4.78%+56.45%+73.31% 663B
-0.20%+1.26%+23.38%+78.92% 462B
+2.09%-2.06%+32.28%+38.37% 344B
0.00%+5.36%+27.40%+47.50% 307B
+1.42%+0.26%-0.52%+13.62% 251B
+0.15%+1.49%+56.25%+74.60% 239B
-0.03%+2.13%-17.30%-53.99% 207B
+0.95%+1.23%+33.36%+100.49% 186B
Average +0.40%-0.51%+25.03%+65.05% 369.58B
Weighted average by Cap. +0.70%-0.84%+38.68%+68.64%

Financials

2026 *2027 *
Net sales 52.93M 45.54M 42.73M 39.1M 72.98M 5B 73.55M 506M 197M 2.56B 199M 194M 8.23B 102M 88.17M 82.74M 75.7M 141M 9.69B 142M 979M 381M 4.95B 385M 376M 15.94B
Net income -334M -288M -270M -247M -461M -31.6B -465M -3.19B -1.24B -16.15B -1.26B -1.23B -52.01B -324M -279M -262M -240M -447M -30.67B -451M -3.1B -1.21B -15.67B -1.22B -1.19B -50.47B
Net Debt -378M -325M -305M -279M -521M -35.73B -525M -3.61B -1.41B -18.26B -1.42B -1.39B -58.81B -66M -56.79M -53.29M -48.76M -91M -6.24B -91.72M -630M -246M -3.19B -248M -242M -10.27B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
03/09/26 US$10.57 -3.02% 763,278
02/09/26 US$10.90 +3.12% 2,068,790
01/09/26 US$10.57 +0.76% 1,578,326
31/08/26 US$10.49 +1.25% 1,520,523
28/08/26 US$10.36 -4.25% 1,563,599
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.90USD
Average target price
27.09USD
Spread / Average Target
+148.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock